US20070173448A1 - Solution for removing cataracts via liquefracture - Google Patents

Solution for removing cataracts via liquefracture Download PDF

Info

Publication number
US20070173448A1
US20070173448A1 US11/565,256 US56525606A US2007173448A1 US 20070173448 A1 US20070173448 A1 US 20070173448A1 US 56525606 A US56525606 A US 56525606A US 2007173448 A1 US2007173448 A1 US 2007173448A1
Authority
US
United States
Prior art keywords
solution
liquefracture
viscosity
hpmc
handpiece
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/565,256
Inventor
Mandar Shah
Glenn Sussman
Donald Cohen
Uday Doshi
Kerry Markwardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/565,256 priority Critical patent/US20070173448A1/en
Publication of US20070173448A1 publication Critical patent/US20070173448A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00736Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments

Definitions

  • the present invention is directed to the field of ophthalmic surgery. More specifically, the invention is directed to the field of procedures and associated products for removing the natural crystalline lens of the human eye in patients whose lenses have become afflicted with cataracts or other conditions wherein removal of the lenses is required.
  • Phcoemulsification Removal of human lenses has been achieved by various surgical techniques in the past.
  • the most prevalent technique at this time involves a process known as “phacoemulsification”.
  • This process involves the use of a handpiece with a tip that vibrates at an ultrasonic frequency. After making a small incision in the eye, the ophthalmic surgeon employs this handpiece to emulsify the lens within the capsular bag of the eye, and then employs the irrigation and aspiration modes of the handpiece to remove the lens particles from the capsular bag. Millions of cataract patients have had their cataractous lenses removed by means of the phacoemulsification procedure.
  • Liquefracture is a new technique wherein the lens is disintegrated by applying hot pulses of a solution to the lens via an irrigation/aspiration handpiece.
  • the handpiece such as those described in the above-cited patents, includes a chamber for heating the solution and generating pulses of heated solution that are expelled from the handpiece.
  • the lens is disintegrated by means of a combination of the heat absorbed from the solution and the force of the pulses of the solution impacting the lens tissue.
  • the solution utilized for this purpose is referred to herein as the “liquefracture solution”.
  • both the extent to which the solution can be heated and the force or velocity of the pulses are necessarily constrained.
  • the stream of hot, pulsed solution is surrounded by a conventional irrigating solution which dissipates both the heat and force of the pulsed solution after it impacts the lens tissue.
  • This second solution is referred to herein as either the “irrigating solution” or the “outer” or “dissipating” solution.
  • the solution utilized for both the liquefracture solution and the irrigating solution has been a conventional balanced salt solution such as BSS® (Balanced Salt Solution) Sterile Irrigating Solution, which is available from Alcon Laboratories, Inc., Fort Worth, Tex.
  • BSS® Balanced Salt Solution
  • Sterile Irrigating Solution Sterile Irrigating Solution
  • the present invention is based on the discovery of a means for enhancing the effectiveness of the liquefracture solution in disintegrating the lens material during the above-described liquefracture procedure. More specifically, it has been discovered that the effectiveness of the liquefracture solution can be enhanced by increasing the pulse force of the solution. The effectiveness of the liquefracture solution can be further enhanced by including an agent which forms a temporarily insoluble precipitate at the temperatures utilized to form the hot, pulsed solution, thereby resulting in particles that act as abrasive agents.
  • the pulse force of the liquefracture solution is increased by including a viscosity-enhancing agent in the solution used to form the hot, pulsed solution, thereby increasing the length of time for which the solution is retained in the heating/expansion chamber of the liquefracture handpiece and permitting more energy to be stored in the pulse of fluid.
  • the pulse force can be further enhanced by including a small amount of a gas-generating propellant in the solution used to form the hot, pulsed solution, thereby increasing the velocity or force of the hot pulsed solution.
  • the effectiveness of the liquefracture procedure is further enhanced by including a viscosity-enhancing agent in the irrigating solution utilized as the outer or dissipating solution in the procedure.
  • the enhanced viscosity of the irrigating solution increases the ability of the solution to dissipate the heat absorbed from the liquefracture solution.
  • the temperature or proportion of the liquefracture solution can be increased (i.e., relative to the irrigating solution), thereby further enhancing the ability of the liquefracture solution to disintegrate the lens material.
  • the increased pulse force of the solutions of the present invention enhances the effectiveness of the liquefracture procedure, relative to the speed at which the lens is disintegrated and the extent to which liquefracture can be utilized to remove relatively hard lenses.
  • the inclusion of an abrasive agent in the solutions further enhances the effectiveness of the liquefracture solution by increasing the ability of the solutions to cut and disintegrate cataractous lens material.
  • the improved liquefracture solutions of the present invention have been discovered as a result of a careful balancing of several factors. For example, the desired goal of enhancing the ability of the liquefracture solution to disintegrate the lens must be balanced against other required physical characteristics of the solution, such as the need for the solution to flow through the liquefracture handpiece and associated surgical equipment during the surgical procedure.
  • a liquefracture solution to disintegrate a cataractous lens is directly dependent on the force of the pulsed solution as it impacts the lens tissue. This force is referred to herein as the “pulse force” of the liquefracture solution.
  • the pulse force of the liquefracture solution can be increased by enhancing the viscosity of the liquefracture solution. Enhancing the viscosity of the liquefracture solution increases the residence time of the solution in the heating chamber of the liquefracture handpiece, thereby increasing the energy absorbed by the solution and increasing the force by which the solution is expulsed from the chamber.
  • agents may be utilized to enhance the viscosity of the liquefracture solution, such as chondroitin sulfate, sodium hyaluronate or other proteoglycans; cellulose derivatives, such as hydroxypropyl methylcellulose (“HPMC”), carboxy methylcellulose (“CMC”), and hydroxyethyl cellulose (“HEC”); collagen and modified collagens; galactomannans, such as guar gum, locust bean gum and tara gum, as well as polysaccharides derived from the foregoing natural gums and similar natural or synthetic gums containing mannose and/or galactose moieties as the main structural components (e.g., hydroxypropyl guar); xanthan gum; gellan gums; alginate; chitosans; polyvinyl alcohol; carboxyvinyl polymers (e.g., carbomers such as the CarbopolTM brand polymers available from B.F.
  • HPMC hydroxypropyl methylcellulose
  • HPMC viscosity-enhancing agent
  • the most preferred viscosity-enhancing agent is HPMC at a molecular weight of 86,000 to 260,000.
  • HPMC is also preferred as the transient abrasive agent of the improved liquefracture solutions described herein.
  • the above-described viscosity-adjusting agents will be utilized in an amount sufficient to provide the liquefracture solutions of the present invention with an enhanced viscosity.
  • enhanced viscosity means a viscosity which is greater than the viscosity of aqueous humor and standard irrigating solutions, both of which generally have viscosities of approximately 1 centipoise (“cps”).
  • the liquefracture solutions of the present invention will typically have viscosities of from greater than 1 cps to about 15 cps, preferably from about 2 to about 7 cps.
  • the liquefracture solutions of the present invention contain one or more of the above-described viscosity enhancing agents in an ophthalmically acceptable vehicle.
  • Various types of solutions may be utilized as a vehicle for the liquefracture solution; however, the conductivity of the liquefracture solution is a factor which must be taken into account relative to selection of an appropriate vehicle.
  • Ionic solutions such as balanced salt solution
  • the conductivity of the solution has to be balanced with instrument design criteria, such as the need to avoid corrosion or other damage to the liquefracture handpiece and avoid clogging of the handpiece or other fluid channels in the ophthalmic surgical operating system.
  • the liquefracture solutions are preferably formulated to be isotonic.
  • the osmolality of the solution is an indirect measure of conductivity, since both properties are dependent on the ionic concentration.
  • the liquefracture solutions of the present invention preferably have an osmolality of from about 200 to about 400 milliosmoles per kilogram of water (mOsm/kg”).
  • the pulse force of the liquefracture solution of the present invention may also be enhanced by the inclusion of a propellant in the solution.
  • the propellant comprises a gas liberating substance, such as sodium bicarbonate or sodium chlorate.
  • the liquefracture solution contains sodium bicarbonate or sodium chlorate in a concentration of from about 1.0 to about 2.5 w/v %.
  • the ability of the liquefracture solutions of the present invention to cut and disintegrate cataractous lens tissue can be further improved by including a transient abrasive agent in the solutions.
  • the transient abrasive agent forms a temporarily insoluble precipitate when heated in the liquefracture handpiece, thereby creating particles that facilitate cutting and disintegration of the cataractous lens when pulses of the hot liquefracture solution are applied to the lens, but returns to solution as the liquefracture solution cools within the eye, thereby facilitating removal of the solution via aspiration.
  • transient abrasive agents This transient, temperature dependent formation of a precipitate within the liquefracture solution significantly enhances the ability of the solution to cut and disintegrate the cataractous lens, without disrupting the operation of the irrigation and aspiration modes of ophthalmic surgical systems.
  • the materials that perform these functions are referred to herein as “transient abrasive agents”.
  • the transient abrasive agent In addition to being physiologically acceptable, generally, and non-toxic to intraocular tissues, specifically, the transient abrasive agent must be: (1) at least partially soluble in aqueous electrolyte solutions at room temperature and body temperature (i.e., temperatures of about 25° C. and 37° C., respectively), (2) substantially insoluble at a temperature greater than 50° C. and (3) chemically stable at the aforementioned temperatures. Materials that meet these criteria are referred to herein as being “an ophthalmically acceptable, transient abrasive agent”.
  • the preferred transient abrasive agents are cellulose derivatives, such as hydroxypropyl methylcellulose (“HPMC”), carboxy methylcellulose (“CMC”) and hydroxyethyl cellulose (“HEC”).
  • HPMC hydroxypropyl methylcellulose
  • CMC carboxy methylcellulose
  • HEC hydroxyethyl cellulose
  • HPMC hydroxypropyl methylcellulose
  • HPMC is preferred based on its unique ability to form a temporarily insoluble precipitate upon heating to temperatures above 50° C.
  • the other cellulose derivatives mentioned above will also form an insoluble precipitate when heated, but only a relatively small portion of these cellulose materials becomes insoluble.
  • concentrations selected will generally be in the range of from about 0.05 to about 0.5 weight/volume percent (w/v %).
  • HPMC hydroxypropyl methylcellulose
  • HPMC is used to enhance the viscosity of the liquefracture solution and also as the transient abrasive agent, then there is an additional constraint, that is, the concentration of HPMC should not be such that its particles would clog the heating chamber of the liquefracture handpiece.
  • concentration of HPMC should not be such that its particles would clog the heating chamber of the liquefracture handpiece.
  • HPMC concentrations of 0.2% or higher may result in a clogging of the irrigation/aspiration system. Consequently, it is preferred to utilize HPMC concentrations of less than 0.2 w/v %.
  • HPMC there is wide molecular weight range for HPMC. Increasing the molecular weight of HPMC will provide a higher viscosity at the same concentration level. In order to achieve the same viscosity, a lower concentration of higher molecular weight HPMC can be used, resulting in a lower number of particles, and hence, less potential for clogging. These two aspects of HPMC must be balanced to achieve an optimum solution. However, the use of relatively high molecular weight forms of HPMC is preferred for the reasons stated above.
  • the overall performance of the liquefracture procedure is further enhanced by utilizing an irrigating solution having an enhanced viscosity as the outer or dissipating solution.
  • an enhanced viscosity solution increases the ability of the solution to dissipate heat from the hot, pulsed liquefracture solution, thereby making it possible to increase the temperature of the liquefracture solution and/or increase the proportion of that solution, relative to the irrigating solution.
  • the viscosity-enhancing agents that may be employed for this purpose are the same as those that may be employed to enhance the viscosity of the liquefracture solution.
  • One or more viscosity-enhancing agents is preferably utilized in an amount sufficient to provide the irrigating solution with a viscosity in the range of from about 2 to about 7 cps.
  • the above-described formulation may be prepared as follows: First, the water for Injection is brought close to boiling or at boiling. The HPMC is then slowly added to the water under continuous stirring to thoroughly disperse it in the water. Then the mixture is slowly allowed to cool, stirring continuously. Once at room temperature, the mixture should start clearing up. Then the mixture is stored overnight in an appropriate container to fully hydrate the HPMC. The following day, the remaining ingredients are added to the HPMC solution, additional water for injection is added if needed to bring the solution to final volume, and the final solution is filtered, packaged in bottles and autoclaved.
  • EXAMPLE 6 Component Amount (w/v %) Function Hydroxypropyl 0.01 to 0.2 VEA/TAA Methylcellulose (HPMC) Sodium Chloride 0.744 Tonicity Agent Potassium Chloride 0.0395 Excipient Dibasic Sodium 0.0433 Buffering Agent Phosphate (Anhydrous) Sodium Bicarbonate 0.219% + 20% xs Excipient Hydrochloric Acid Adjust pH pH Adjust Sodium Hydroxide To 7.0-7.2 pH Adjust Water for Injection 100% Vehicle
  • the above-described formulation may be prepared utilizing the method described in Example 1, above.
  • the data set forth in the following table demonstrates the increased pulse force that is achieved by the present invention. More specifically, the data show that the addition of a gas-generating propellant (i.e., sodium bicarbonate) enhances the pulse force of a liquefracture solution upon expulsion from the liquefracture handpiece, and show that the addition of a viscosity-enhancing agent (i.e., HPMC) to the liquefracture solution further increases pulse force.
  • a gas-generating propellant i.e., sodium bicarbonate
  • HPMC viscosity-enhancing agent
  • the pulse force evaluations were carried out using an appropriate load cell with an analog-filtered signal, using the following parameters: 10,000 scans/second; 2,000 Hz sampling frequency with 25 Hz high pass cutoff frequency; 2500 Hz low pass cutoff frequency and 2,000 points collected.
  • the full-scale pulse force is measured from the baseline to the maximum height of the filtered signal, which is a relative measurement and not an absolute one.
  • the electrode or engine was a standard one of the type described U.S. Pat. Nos. 5,989,212; 5,997,499; and 6,080,128 (Sussman et al.), the contents of which have been incorporated herein by reference.
  • the graphite electrodes were set at a pulse duration of 1.7 milliseconds.
  • passive pressure was adjusted such that the passive flow rate was in the range of 3 to 4 grams per minute (“gms/min”) for optimal performance of the instrument.
  • the effect of the molecular weight of the viscosity enhancing agents on the pulse force of the liquefracture solutions was evaluated by measuring and comparing the pulse forces of solutions containing three different cellulose derivatives, CMC, HPMC and HEC. Solutions containing two different molecular weights of each cellulose derivative were prepared using standard formulation procedures. The concentration of the cellulose polymers was adjusted in order to eliminate differences in viscosity between the test solutions. A standard ophthalmic irrigating solution, BSS® (Balanced Salt Solution) Sterile Irrigation Solution, was utilized as the control against which the enhanced viscosity solutions were measured. The pulse force of the solutions was determined by means of the procedures described in Example 7. The pulse force values for the test solutions were compared to the pulse force value for the control solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

An improved solution for use in the removal of cataractous lenses via liquefracture is described. The liquefracture solution contains a viscosity-enhancing agent to increase the residence time of the solution in the heating chamber of the liquefracture handpiece, thereby increasing the expulsion force of the solution from the handpiece (i.e., “pulse force”). An agent that releases gas when the liquefracture solution is heated in the handpiece may also be included in the solution, thereby also enhancing the pulse force of the solution upon expulsion from the handpiece. The solution preferably also contains a partially water-soluble agent that forms a temporarily insoluble precipitate when heated in a liquefracture handpiece. The precipitate acts as an abrasive agent when expelled with the liquefracture solution from the handpiece, thereby facilitating the cutting and disintegration of the cataractous lens material.

Description

  • This application is a divisional of application Ser. No. 10/433,166 filed May 30, 2003, which itself claims priority from and incorporates by reference commonly owned PCT application Ser. No. US01/47635 filed Dec. 11, 2001, and provisional application Ser. No. 60/257,715, filed Dec. 20, 2000.
  • BACKGROUND OF THE INVENTION
  • The present invention is directed to the field of ophthalmic surgery. More specifically, the invention is directed to the field of procedures and associated products for removing the natural crystalline lens of the human eye in patients whose lenses have become afflicted with cataracts or other conditions wherein removal of the lenses is required.
  • Removal of human lenses has been achieved by various surgical techniques in the past. The most prevalent technique at this time involves a process known as “phacoemulsification”. This process involves the use of a handpiece with a tip that vibrates at an ultrasonic frequency. After making a small incision in the eye, the ophthalmic surgeon employs this handpiece to emulsify the lens within the capsular bag of the eye, and then employs the irrigation and aspiration modes of the handpiece to remove the lens particles from the capsular bag. Millions of cataract patients have had their cataractous lenses removed by means of the phacoemulsification procedure. Although ophthalmic surgeons have mastered the use of the phacoemulsification handpiece and associated surgical techniques, the use of an ultrasonic needle or tip within the eye presents inherent risks and concerns. Ophthalmic surgeons and others skilled in the art have therefore searched for improved devices and procedures for removing the human lens.
  • A new lens removal procedure known as “liquefracture” is currently being developed by Alcon Research, Ltd. This procedure is described in U.S. Pat. No. 5,616,120 (Andrew, et al.), U.S. Pat. No. 5,885,243 (Capetan, et al.), U.S. Pat. No. 5,989,212 (Sussman, et al.), U.S. Pat. No. 5,997,499 (Sussman, et al.) and U.S. Pat. No. 6,080,128 (Sussman, et al.), the entire contents of the foregoing patents are hereby incorporated in the present specification by reference.
  • Liquefracture is a new technique wherein the lens is disintegrated by applying hot pulses of a solution to the lens via an irrigation/aspiration handpiece. The handpiece, such as those described in the above-cited patents, includes a chamber for heating the solution and generating pulses of heated solution that are expelled from the handpiece. The lens is disintegrated by means of a combination of the heat absorbed from the solution and the force of the pulses of the solution impacting the lens tissue. The solution utilized for this purpose is referred to herein as the “liquefracture solution”.
  • Due to the delicacy of the intraocular tissues, both the extent to which the solution can be heated and the force or velocity of the pulses are necessarily constrained. In order to prevent damage to surrounding tissues, the stream of hot, pulsed solution is surrounded by a conventional irrigating solution which dissipates both the heat and force of the pulsed solution after it impacts the lens tissue. This second solution is referred to herein as either the “irrigating solution” or the “outer” or “dissipating” solution.
  • Prior to the present invention, the solution utilized for both the liquefracture solution and the irrigating solution has been a conventional balanced salt solution such as BSS® (Balanced Salt Solution) Sterile Irrigating Solution, which is available from Alcon Laboratories, Inc., Fort Worth, Tex. Although this type of solution is generally adequate, there is a need for improved solutions which enhance the disintegration of the lens with the pulsed, heated solution and facilitate removal of the lens fragments following disintegration of the lens. The present invention is directed to filling this need.
  • SUMMARY OF THE INVENTION
  • The present invention is based on the discovery of a means for enhancing the effectiveness of the liquefracture solution in disintegrating the lens material during the above-described liquefracture procedure. More specifically, it has been discovered that the effectiveness of the liquefracture solution can be enhanced by increasing the pulse force of the solution. The effectiveness of the liquefracture solution can be further enhanced by including an agent which forms a temporarily insoluble precipitate at the temperatures utilized to form the hot, pulsed solution, thereby resulting in particles that act as abrasive agents.
  • The pulse force of the liquefracture solution is increased by including a viscosity-enhancing agent in the solution used to form the hot, pulsed solution, thereby increasing the length of time for which the solution is retained in the heating/expansion chamber of the liquefracture handpiece and permitting more energy to be stored in the pulse of fluid. The pulse force can be further enhanced by including a small amount of a gas-generating propellant in the solution used to form the hot, pulsed solution, thereby increasing the velocity or force of the hot pulsed solution.
  • In a preferred embodiment of the present invention, the effectiveness of the liquefracture procedure is further enhanced by including a viscosity-enhancing agent in the irrigating solution utilized as the outer or dissipating solution in the procedure. The enhanced viscosity of the irrigating solution increases the ability of the solution to dissipate the heat absorbed from the liquefracture solution. As a result, the temperature or proportion of the liquefracture solution can be increased (i.e., relative to the irrigating solution), thereby further enhancing the ability of the liquefracture solution to disintegrate the lens material.
  • The increased pulse force of the solutions of the present invention enhances the effectiveness of the liquefracture procedure, relative to the speed at which the lens is disintegrated and the extent to which liquefracture can be utilized to remove relatively hard lenses. The inclusion of an abrasive agent in the solutions further enhances the effectiveness of the liquefracture solution by increasing the ability of the solutions to cut and disintegrate cataractous lens material.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The improved liquefracture solutions of the present invention have been discovered as a result of a careful balancing of several factors. For example, the desired goal of enhancing the ability of the liquefracture solution to disintegrate the lens must be balanced against other required physical characteristics of the solution, such as the need for the solution to flow through the liquefracture handpiece and associated surgical equipment during the surgical procedure.
  • The ability of a liquefracture solution to disintegrate a cataractous lens is directly dependent on the force of the pulsed solution as it impacts the lens tissue. This force is referred to herein as the “pulse force” of the liquefracture solution. As indicated above, it has been discovered that the pulse force of the liquefracture solution can be increased by enhancing the viscosity of the liquefracture solution. Enhancing the viscosity of the liquefracture solution increases the residence time of the solution in the heating chamber of the liquefracture handpiece, thereby increasing the energy absorbed by the solution and increasing the force by which the solution is expulsed from the chamber.
  • Various types of agents may be utilized to enhance the viscosity of the liquefracture solution, such as chondroitin sulfate, sodium hyaluronate or other proteoglycans; cellulose derivatives, such as hydroxypropyl methylcellulose (“HPMC”), carboxy methylcellulose (“CMC”), and hydroxyethyl cellulose (“HEC”); collagen and modified collagens; galactomannans, such as guar gum, locust bean gum and tara gum, as well as polysaccharides derived from the foregoing natural gums and similar natural or synthetic gums containing mannose and/or galactose moieties as the main structural components (e.g., hydroxypropyl guar); xanthan gum; gellan gums; alginate; chitosans; polyvinyl alcohol; carboxyvinyl polymers (e.g., carbomers such as the Carbopol™ brand polymers available from B.F. Goodrich); and various other viscous or viscoelastomeric substances, including but not limited to those described in U.S. Pat. No. 5,409,904 (Hecht, et al.), the entire contents of which are hereby incorporated by reference in the present specification.
  • The following patent publications may be referred to for further details concerning the above-listed viscosity-enhancing agents: U.S. Pat. No. 4,861,760 (gellan gums); U.S. Pat. No. 4,255,415 and WIPO Publication No. WO 94/10976 (polyvinyl alcohol); U.S. Pat. No. 4,271,143 (carboxyvinyl polymers); WIPO Publication No. WO 99/51273 (xanthan gum); and WIPO Publication No. WO 99/06023 (galactomannans). The entire contents of the foregoing references pertaining to the structures, chemical properties and physical properties of the respective viscosity enhancing agents described above are hereby incorporated in the present specification by reference.
  • As demonstrated in Example 8 below, it has been found that the use of higher molecular weight fractions of polymeric materials as the viscosity enhancing agent is desirable, because the higher molecular weight fractions generally produce greater pulse forces than lower molecular weight fractions of the same material. The use of higher molecular weight fractions is therefore preferred.
  • The most preferred viscosity-enhancing agent is HPMC at a molecular weight of 86,000 to 260,000. As discussed below, HPMC is also preferred as the transient abrasive agent of the improved liquefracture solutions described herein.
  • The above-described viscosity-adjusting agents will be utilized in an amount sufficient to provide the liquefracture solutions of the present invention with an enhanced viscosity. As utilized herein, the phrase “enhanced viscosity” means a viscosity which is greater than the viscosity of aqueous humor and standard irrigating solutions, both of which generally have viscosities of approximately 1 centipoise (“cps”). The liquefracture solutions of the present invention will typically have viscosities of from greater than 1 cps to about 15 cps, preferably from about 2 to about 7 cps.
  • The liquefracture solutions of the present invention contain one or more of the above-described viscosity enhancing agents in an ophthalmically acceptable vehicle. Various types of solutions may be utilized as a vehicle for the liquefracture solution; however, the conductivity of the liquefracture solution is a factor which must be taken into account relative to selection of an appropriate vehicle.
  • Due to the very high resistance of water, which results in low conductivity, water does not heat up sufficiently and thus does not produce adequate pulse force for liquefracture procedures. Ionic solutions, such as balanced salt solution, have relatively lower resistance to electricity, and therefore have higher conductivity. This higher conductivity allows the ionic salt solutions to be heated sufficiently to be utilized in liquefracture. However, the conductivity of the solution has to be balanced with instrument design criteria, such as the need to avoid corrosion or other damage to the liquefracture handpiece and avoid clogging of the handpiece or other fluid channels in the ophthalmic surgical operating system.
  • The liquefracture solutions are preferably formulated to be isotonic. The osmolality of the solution is an indirect measure of conductivity, since both properties are dependent on the ionic concentration. The liquefracture solutions of the present invention preferably have an osmolality of from about 200 to about 400 milliosmoles per kilogram of water (mOsm/kg”).
  • As indicated above, the pulse force of the liquefracture solution of the present invention may also be enhanced by the inclusion of a propellant in the solution. The propellant comprises a gas liberating substance, such as sodium bicarbonate or sodium chlorate. In a preferred embodiment of the present invention, the liquefracture solution contains sodium bicarbonate or sodium chlorate in a concentration of from about 1.0 to about 2.5 w/v %.
  • The ability of the liquefracture solutions of the present invention to cut and disintegrate cataractous lens tissue can be further improved by including a transient abrasive agent in the solutions. The transient abrasive agent forms a temporarily insoluble precipitate when heated in the liquefracture handpiece, thereby creating particles that facilitate cutting and disintegration of the cataractous lens when pulses of the hot liquefracture solution are applied to the lens, but returns to solution as the liquefracture solution cools within the eye, thereby facilitating removal of the solution via aspiration. This transient, temperature dependent formation of a precipitate within the liquefracture solution significantly enhances the ability of the solution to cut and disintegrate the cataractous lens, without disrupting the operation of the irrigation and aspiration modes of ophthalmic surgical systems. The materials that perform these functions are referred to herein as “transient abrasive agents”.
  • Various physiologically acceptable materials may be utilized as the transient abrasive agent. In addition to being physiologically acceptable, generally, and non-toxic to intraocular tissues, specifically, the transient abrasive agent must be: (1) at least partially soluble in aqueous electrolyte solutions at room temperature and body temperature (i.e., temperatures of about 25° C. and 37° C., respectively), (2) substantially insoluble at a temperature greater than 50° C. and (3) chemically stable at the aforementioned temperatures. Materials that meet these criteria are referred to herein as being “an ophthalmically acceptable, transient abrasive agent”.
  • The preferred transient abrasive agents are cellulose derivatives, such as hydroxypropyl methylcellulose (“HPMC”), carboxy methylcellulose (“CMC”) and hydroxyethyl cellulose (“HEC”). The most preferred cellulose derivative is HPMC. HPMC is preferred based on its unique ability to form a temporarily insoluble precipitate upon heating to temperatures above 50° C. The other cellulose derivatives mentioned above will also form an insoluble precipitate when heated, but only a relatively small portion of these cellulose materials becomes insoluble.
  • The selection of an ideal concentration for each class or type of transient abrasive agent requires a balancing of the above-cited factors. However, the concentrations selected will generally be in the range of from about 0.05 to about 0.5 weight/volume percent (w/v %).
  • In a preferred embodiment of the present invention, hydroxypropyl methylcellulose (“HPMC”) is utilized as the transient abrasive agent, and also increases the viscosity of the liquefracture solution, thereby enhancing both the pulse force and cutting action of the liquefracture solution.
  • As indicated above, it is necessary to achieve a balance between enhancing the pulse force of the liquefracture solution, and maintaining a solution viscosity which is acceptable for use with the irrigating/aspiration systems employed in intraocular surgical procedures. If HPMC is used to enhance the viscosity of the liquefracture solution and also as the transient abrasive agent, then there is an additional constraint, that is, the concentration of HPMC should not be such that its particles would clog the heating chamber of the liquefracture handpiece. The use of HPMC concentrations of 0.2% or higher may result in a clogging of the irrigation/aspiration system. Consequently, it is preferred to utilize HPMC concentrations of less than 0.2 w/v %.
  • It should be noted that there is wide molecular weight range for HPMC. Increasing the molecular weight of HPMC will provide a higher viscosity at the same concentration level. In order to achieve the same viscosity, a lower concentration of higher molecular weight HPMC can be used, resulting in a lower number of particles, and hence, less potential for clogging. These two aspects of HPMC must be balanced to achieve an optimum solution. However, the use of relatively high molecular weight forms of HPMC is preferred for the reasons stated above.
  • In a preferred embodiment of the present invention, the overall performance of the liquefracture procedure is further enhanced by utilizing an irrigating solution having an enhanced viscosity as the outer or dissipating solution. The use of an enhanced viscosity solution increases the ability of the solution to dissipate heat from the hot, pulsed liquefracture solution, thereby making it possible to increase the temperature of the liquefracture solution and/or increase the proportion of that solution, relative to the irrigating solution. The viscosity-enhancing agents that may be employed for this purpose are the same as those that may be employed to enhance the viscosity of the liquefracture solution. One or more viscosity-enhancing agents is preferably utilized in an amount sufficient to provide the irrigating solution with a viscosity in the range of from about 2 to about 7 cps.
  • The following examples are provided to further illustrate the liquefracture solutions of the present invention.
    EXAMPLE 1
    Component Amount (w/v %) Function
    HPMC (E4M) 0.05 to 0.2 VEA/TAA*
    Sodium Bicarbonate 1.5 Propellant
    Hydrochloric Acid Adjust pH pH Adjust
    Sodium Hydroxide Adjust pH pH Adjust
    Water for Injection 100% Vehicle

    *VEA/TAA = Viscosity Enhancing Agent/Transient Abrasive Agent
  • The above-described formulation may be prepared as follows: First, the water for Injection is brought close to boiling or at boiling. The HPMC is then slowly added to the water under continuous stirring to thoroughly disperse it in the water. Then the mixture is slowly allowed to cool, stirring continuously. Once at room temperature, the mixture should start clearing up. Then the mixture is stored overnight in an appropriate container to fully hydrate the HPMC. The following day, the remaining ingredients are added to the HPMC solution, additional water for injection is added if needed to bring the solution to final volume, and the final solution is filtered, packaged in bottles and autoclaved.
    EXAMPLE 2
    Component Amount (w/v %) Function
    HPMC (K100M) 0.05 to 0.2 VEA/TAA
    Sodium Bicarbonate 1.5 Propellant
    Hydrochloric Acid Adjust pH PH Adjust
    Sodium Hydroxide Adjust pH PH Adjust
    Water for Injection 100% Vehicle
  • The above-described formulation may be prepared utilizing the method described in Example 1, above.
    EXAMPLE 3
    Component Amount (w/v %) Function
    HPMC (E4M) 0.05 to 0.2 VEA/TAA
    Sodium Chloride 0.9 Tonicity Agent
    Water for Injection 100% Vehicle
  • The above-described formulation may be prepared utilizing the method described in Example 1, above.
    EXAMPLE 4
    Component Amount (w/v %) Function
    HPMC (K100M) 0.05 to 0.2 VEA/TAA
    Sodium Chloride 0.9 Tonicity Agent
    Water for Injection 100% Vehicle
  • The above-described formulation may be prepared utilizing the method described in Example 1, above.
    EXAMPLE 5
    Component Amount (w/v %) Function
    HPMC (K100M) 0.01 to 0.2 VEA/TAA
    Sodium Chloride 0.64 Tonicity Agent
    Potassium Chloride 0.075 Tonicity Agent
    Calcium Chloride (Dihydrate) 0.048 Buffering Agent
    Magnesium Chloride 0.03 Buffering Agent
    (Hexahydrate)
    Sodium Acetate (Trihydrate) 0.39 Buffering Agent
    Sodium Citrate (Dihydrate) 0.17 Buffering Agent
    Hydrochloric Acid Adjust pH pH Adjust
    Sodium Hydroxide To 7.0-7.2 pH Adjust
    Water for Injection Qsd to 100 Vehicle
  • The above-described formulation may be prepared utilizing the method described in Example 1, above.
    EXAMPLE 6
    Component Amount (w/v %) Function
    Hydroxypropyl 0.01 to 0.2 VEA/TAA
    Methylcellulose (HPMC)
    Sodium Chloride 0.744 Tonicity Agent
    Potassium Chloride 0.0395 Excipient
    Dibasic Sodium 0.0433 Buffering Agent
    Phosphate (Anhydrous)
    Sodium Bicarbonate 0.219% + 20% xs Excipient
    Hydrochloric Acid Adjust pH pH Adjust
    Sodium Hydroxide To 7.0-7.2 pH Adjust
    Water for Injection 100% Vehicle
  • The above-described formulation may be prepared utilizing the method described in Example 1, above.
  • EXAMPLE 7
  • The data set forth in the following table demonstrates the increased pulse force that is achieved by the present invention. More specifically, the data show that the addition of a gas-generating propellant (i.e., sodium bicarbonate) enhances the pulse force of a liquefracture solution upon expulsion from the liquefracture handpiece, and show that the addition of a viscosity-enhancing agent (i.e., HPMC) to the liquefracture solution further increases pulse force.
    TABLE 1
    Pulse Force Passive Flow
    Formulation Description (g) (gms/min)
    Distilled Water 0 3.44
    BSS ® 5-5.5 3.44
    BSS PLUS ® (Part I) 5.5 3.36
    1% NaHCO3 6.0 3.13
    1% NaHCO3 + 0.1% HPMC 6.75 3.96
    (E4M grade)
    1.5% NaHCO3 + 0.1% 7.1 4.1
    HPMC (E4M grade)
    1% NaHCO3 + 0.2% HPMC 8.0 4.0
    (E4M Grade)
    1.5% NaHCO3 + 0.05% 8.2 4.4
    HPMC (K100M grade)
    BSS PLUS Part I + 0.1% 8.5 3.96
    HPMC
  • The pulse force evaluations were carried out using an appropriate load cell with an analog-filtered signal, using the following parameters: 10,000 scans/second; 2,000 Hz sampling frequency with 25 Hz high pass cutoff frequency; 2500 Hz low pass cutoff frequency and 2,000 points collected. The full-scale pulse force is measured from the baseline to the maximum height of the filtered signal, which is a relative measurement and not an absolute one.
  • The electrode or engine was a standard one of the type described U.S. Pat. Nos. 5,989,212; 5,997,499; and 6,080,128 (Sussman et al.), the contents of which have been incorporated herein by reference. The graphite electrodes were set at a pulse duration of 1.7 milliseconds. During the measurement, passive pressure was adjusted such that the passive flow rate was in the range of 3 to 4 grams per minute (“gms/min”) for optimal performance of the instrument.
  • EXAMPLE 8
  • The effect of the molecular weight of the viscosity enhancing agents on the pulse force of the liquefracture solutions was evaluated by measuring and comparing the pulse forces of solutions containing three different cellulose derivatives, CMC, HPMC and HEC. Solutions containing two different molecular weights of each cellulose derivative were prepared using standard formulation procedures. The concentration of the cellulose polymers was adjusted in order to eliminate differences in viscosity between the test solutions. A standard ophthalmic irrigating solution, BSS® (Balanced Salt Solution) Sterile Irrigation Solution, was utilized as the control against which the enhanced viscosity solutions were measured. The pulse force of the solutions was determined by means of the procedures described in Example 7. The pulse force values for the test solutions were compared to the pulse force value for the control solution. All of the test solutions demonstrated an increase in pulse force, relative to the control solution. The results, expressed as percent increase in pulse force, are presented in Table 2 below:
    TABLE 2
    Effect of Molecular Weight on Pulse Force
    Viscosity Increase in Pulse
    Solution (cps) Mol. Wt. Force (%)
    BSS ® Solution 1.0
    0.63% NaCMC (7LFPH) 3.0 ± 0.1 90,000 35
    0.18% NaCMC (7HFPH) 3.0 ± 0.1 700,000 67
    0.2% HPMC (E4M) 2.9 ± 0.1 86,000 45
    0.09% HPMC (K100M) 3.0 ± 0.1 260,000 105
    0.125% HEC (250M) 3.0 ± 0.1 720,000 75
    0.075% HEC (250 HX) 3.0 ± 0.1 1,300,000 82
  • The results set forth in Table 2 demonstrate that for a given cellulose derivative, the use of a higher molecular weight fraction of that derivative results in a greater pulse force. This relationship between molecular weight and pulse force may be attributable to the fact that the higher molecular weight polymer material makes the liquefracture solution more cohesive, thereby resulting in a more concentrated force when the heated solution is expelled from the liquefracture handpiece.
  • The results in Table 2 show that the solution containing HPMC at a molecular weight of 260,000 exhibited a higher pulse force than the solutions containing CMC and HEC at higher molecular weights (i.e., molecular weights of about 700,000). This is believed to be attributable to the fact that the HPMC is acting as both a viscosity enhancing agent and as a transient abrasive agent, and the fact that HPMC is much more effective than CMC or HEC as a transient abrasive agent, as discussed above.

Claims (13)

1. A method of removing a cataract by means of liquefracture, which comprises utilizing in said method a liquefracture solution comprising:
a viscosity enhancing agent in an amount sufficient to increase the residence time of the liquefracture solution in a heating chamber of a liquefracture handpiece, when said solution is heated in said chamber;
an ophthalmically acceptable, conductive vehicle for said viscosity-enhancing agent; and
an effective amount of an ophthalmically acceptable, transient abrasive agent.
2. A method according to claim 1, wherein the ophthalmically acceptable vehicle comprises a balanced salt solution.
3. A method according to claim 2, wherein the liquefracture solution has an osmolality of 200 to 200 mOsm/kg.
4. A method according to claim 2, wherein the liquefracture solution has a viscosity of from greater than 1 cps to 15 cps.
5. A method according to claim 4, wherein the liquefracture solution has a viscosity of from 2 to 7 cps.
6. A method according to claim 1, wherein the viscosity enhancing agent is selected form the group consisting of proteoglycans, cellulose derivatives, collagen and modified collagens, galactomannans, xanthan gum, gellan gums, alginate, chitosans, polyvinyl alcohol, carboxy vinyl polymers, and combinations thereof.
7. A method according to claim 6, wherein the viscosity enhancing agent is a cellulose derivative.
8. A method according to claim 7, wherein the cellulose derivative is selected from the group consisting of HPMC, CMC, HEC and combinations thereof.
9. A method according to claim 8, wherein the cellulose derivative comprises HPMC.
10. A method according to claim 9, wherein the HPMC has a molecular weight in the range of 86,000 to 260,000.
11. A method according to claim 1, wherein the transient abrasive agent is a cellulose derivative.
12. A method according to claim 11, wherein the cellulose derivative comprises HPMC.
13. A method according to claim 1, wherein the liquefracture solution further comprises an amount of gas-generating agent sufficient to enhance the pulse force of the solution upon expulsion of the solution from a liquefracture handpiece.
US11/565,256 2000-12-20 2006-11-30 Solution for removing cataracts via liquefracture Abandoned US20070173448A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/565,256 US20070173448A1 (en) 2000-12-20 2006-11-30 Solution for removing cataracts via liquefracture

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25771500P 2000-12-20 2000-12-20
PCT/US2001/047635 WO2002049552A2 (en) 2000-12-20 2001-12-11 Solution for removing cataracts via liquefracture
US10/433,166 US7169755B2 (en) 2000-12-20 2001-12-11 Solution for removing cataracts via liquefracture
US11/565,256 US20070173448A1 (en) 2000-12-20 2006-11-30 Solution for removing cataracts via liquefracture

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/047635 Division WO2002049552A2 (en) 2000-12-20 2001-12-11 Solution for removing cataracts via liquefracture
US10/433,166 Division US7169755B2 (en) 2000-12-20 2001-12-11 Solution for removing cataracts via liquefracture

Publications (1)

Publication Number Publication Date
US20070173448A1 true US20070173448A1 (en) 2007-07-26

Family

ID=22977445

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/433,166 Expired - Lifetime US7169755B2 (en) 2000-12-20 2001-12-11 Solution for removing cataracts via liquefracture
US11/565,256 Abandoned US20070173448A1 (en) 2000-12-20 2006-11-30 Solution for removing cataracts via liquefracture

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/433,166 Expired - Lifetime US7169755B2 (en) 2000-12-20 2001-12-11 Solution for removing cataracts via liquefracture

Country Status (8)

Country Link
US (2) US7169755B2 (en)
EP (1) EP1343444B1 (en)
JP (1) JP4169596B2 (en)
AU (2) AU2002228955B2 (en)
CA (1) CA2431367C (en)
ES (1) ES2435510T3 (en)
TW (1) TWI298633B (en)
WO (1) WO2002049552A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009048681A2 (en) * 2007-08-06 2009-04-16 The Regents Of The University Of California Methods of tissue-based diagnosis
US20110212485A1 (en) * 2009-02-13 2011-09-01 The Regents Of The University Of California System, method and device for tissue-based diagnosis
US8389582B2 (en) 2007-08-06 2013-03-05 Samir Mitragotri Composition for solubilizing tissue comprising 3-(decyl dimethyl ammonio) propane sulfonate and tetraethylene glycol dodecyl ether
US8609041B2 (en) 2007-08-06 2013-12-17 Samir Mitragotri Apparatus for solubilizing tissue
US8642664B2 (en) 2007-08-06 2014-02-04 Samir Mitragotri Composition for solubilizing tissue and cells comprising N-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate and polyoxyethylene (10) cetyl ether
US9814422B2 (en) 2007-08-06 2017-11-14 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258955A1 (en) * 2000-12-20 2009-10-15 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
US8689439B2 (en) 2010-08-06 2014-04-08 Abbott Laboratories Method for forming a tube for use with a pump delivery system
US8377000B2 (en) 2010-10-01 2013-02-19 Abbott Laboratories Enteral feeding apparatus having a feeding set
US8377001B2 (en) 2010-10-01 2013-02-19 Abbott Laboratories Feeding set for a peristaltic pump system
WO2020068705A1 (en) 2018-09-25 2020-04-02 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
BR112021024952A2 (en) * 2019-06-10 2022-02-15 Ponce De Leon Health Designated Activity Company Alpha-ketoglutarate sustained-release compositions

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238482A (en) * 1978-09-29 1980-12-09 Peyman Gholam A Intraocular infusion irrigation solution and method
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4861760A (en) * 1985-10-03 1989-08-29 Merck & Co., Inc. Ophthalmological composition of the type which undergoes liquid-gel phase transition
US4965253A (en) * 1987-10-14 1990-10-23 University Of Florida Viscoelastic material for ophthalmic surgery
US4983585A (en) * 1987-05-04 1991-01-08 Mdr Group, Inc. Viscoelastic fluid for use in surgery and other therapies and method of using same
US5068225A (en) * 1987-05-04 1991-11-26 Mdr Group, Inc. Viscoelastic fluid for use in surgery and other therapies and method of using same
US5156839A (en) * 1987-05-04 1992-10-20 Mdr Group, Inc. Viscoelastic fluid for use in spine and general surgery and other surgery and therapies and method of using same
US5409904A (en) * 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
US5616120A (en) * 1995-02-06 1997-04-01 Andrew; Mark S. Method and apparatus for lenticular liquefaction and aspiration
US5885243A (en) * 1996-12-11 1999-03-23 Alcon Laboratories, Inc. Liquefaction handpiece
US5989212A (en) * 1998-06-04 1999-11-23 Alcon Laboratories, Inc. Pumping chamber for a liquefaction handpiece having a countersink electrode
US5997499A (en) * 1998-06-04 1999-12-07 Alcon Laboratories, Inc. Tip for a liquefaction handpiece
US6080128A (en) * 1998-06-04 2000-06-27 Alcon Laboratories, Inc. Liquefaction handpiece
US6177544B1 (en) * 1997-08-18 2001-01-23 Koken Co Ltd Collagen-based auxiliary agent for ophthalmic surgery
US6261547B1 (en) * 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6403609B1 (en) * 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0657245B2 (en) * 1986-05-14 1994-08-03 ト−メ−産業株式会社 Viscoelastic solution for ophthalmic surgery
CA1317226C (en) 1987-05-04 1993-05-04 Phillip E. Pennell Viscoelastic fluid for ophthalmic surgery and method of using same
US5273056A (en) * 1992-06-12 1993-12-28 Alcon Laboratories, Inc. Use of combinations of viscoelastics during surgery
AU5599594A (en) 1992-11-16 1994-06-08 Ciba-Geigy Ag Polyvinyl alcohol/borate ophthalmic drug delivery system
DK0732913T3 (en) * 1993-04-30 2003-06-16 Nestle Sa Synthetic viscoelastic material for physiological applications, such as ophthalmic applications
JPH09301891A (en) * 1996-03-15 1997-11-25 Senju Pharmaceut Co Ltd Ocular axial length control agent, preventive and therapeutic agent for hypometropia or hypermetropia
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
EP0909766A3 (en) * 1997-10-15 1999-09-29 Borchers GmbH Urethane-modified non ionic celluloses, a process for their production and their use as thickening additive
EP0976211B1 (en) * 1998-01-16 2007-02-28 Symbol Technologies, Inc. Infrastructure for wireless lans
DE69909768T2 (en) 1998-04-07 2004-06-17 Alcon Manufacturing Ltd., Fort Worth XANTHAN GUM CONTAINING YELLOWING OPHTHALMIC COMPOSITIONS
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US6179805B1 (en) * 1998-06-04 2001-01-30 Alcon Laboratories, Inc. Liquefracture handpiece
CA2269263A1 (en) * 1998-06-04 1999-12-04 Alcon Laboratories, Inc. Control system for a liquefaction handpiece
US6217896B1 (en) * 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4238482A (en) * 1978-09-29 1980-12-09 Peyman Gholam A Intraocular infusion irrigation solution and method
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US5578578A (en) * 1984-11-13 1996-11-26 Alcon Laboratories, Inc. Ophthalmic solutions
US5409904A (en) * 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
US4861760A (en) * 1985-10-03 1989-08-29 Merck & Co., Inc. Ophthalmological composition of the type which undergoes liquid-gel phase transition
US4983585A (en) * 1987-05-04 1991-01-08 Mdr Group, Inc. Viscoelastic fluid for use in surgery and other therapies and method of using same
US5068225A (en) * 1987-05-04 1991-11-26 Mdr Group, Inc. Viscoelastic fluid for use in surgery and other therapies and method of using same
US5156839A (en) * 1987-05-04 1992-10-20 Mdr Group, Inc. Viscoelastic fluid for use in spine and general surgery and other surgery and therapies and method of using same
US4965253A (en) * 1987-10-14 1990-10-23 University Of Florida Viscoelastic material for ophthalmic surgery
US5616120A (en) * 1995-02-06 1997-04-01 Andrew; Mark S. Method and apparatus for lenticular liquefaction and aspiration
US6074358A (en) * 1995-02-06 2000-06-13 Andrew; Mark S. Method and apparatus for lenticular liquefaction and aspiration
US5885243A (en) * 1996-12-11 1999-03-23 Alcon Laboratories, Inc. Liquefaction handpiece
US6403609B1 (en) * 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
US6177544B1 (en) * 1997-08-18 2001-01-23 Koken Co Ltd Collagen-based auxiliary agent for ophthalmic surgery
US6261547B1 (en) * 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US5989212A (en) * 1998-06-04 1999-11-23 Alcon Laboratories, Inc. Pumping chamber for a liquefaction handpiece having a countersink electrode
US5997499A (en) * 1998-06-04 1999-12-07 Alcon Laboratories, Inc. Tip for a liquefaction handpiece
US6080128A (en) * 1998-06-04 2000-06-27 Alcon Laboratories, Inc. Liquefaction handpiece

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009048681A2 (en) * 2007-08-06 2009-04-16 The Regents Of The University Of California Methods of tissue-based diagnosis
WO2009048681A3 (en) * 2007-08-06 2010-01-07 The Regents Of The University Of California Methods of tissue-based diagnosis
US20100261176A1 (en) * 2007-08-06 2010-10-14 Mitragotri Samir M Methods of Tissue-Based Diagnosis
US8389582B2 (en) 2007-08-06 2013-03-05 Samir Mitragotri Composition for solubilizing tissue comprising 3-(decyl dimethyl ammonio) propane sulfonate and tetraethylene glycol dodecyl ether
US8609041B2 (en) 2007-08-06 2013-12-17 Samir Mitragotri Apparatus for solubilizing tissue
US8642664B2 (en) 2007-08-06 2014-02-04 Samir Mitragotri Composition for solubilizing tissue and cells comprising N-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate and polyoxyethylene (10) cetyl ether
US9814422B2 (en) 2007-08-06 2017-11-14 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue
US9909098B2 (en) 2007-08-06 2018-03-06 The Regents Of The University Of California Methods of tissue-based diagnosis
US20110212485A1 (en) * 2009-02-13 2011-09-01 The Regents Of The University Of California System, method and device for tissue-based diagnosis
US8945482B2 (en) 2009-02-13 2015-02-03 The Regents Of The University Of California System, method and device for tissue-based diagnosis
US9328324B2 (en) 2009-02-13 2016-05-03 The Regents Of The University Of California System, method and devices for tissue-based diagnosis
US9848853B2 (en) 2009-02-13 2017-12-26 The Regents Of The University Of California System, method and devices for tissue-based diagnosis

Also Published As

Publication number Publication date
CA2431367C (en) 2010-02-09
CA2431367A1 (en) 2002-06-27
AU2002228955B2 (en) 2005-09-29
EP1343444A2 (en) 2003-09-17
WO2002049552A3 (en) 2003-03-27
TWI298633B (en) 2008-07-11
JP4169596B2 (en) 2008-10-22
JP2004530456A (en) 2004-10-07
ES2435510T3 (en) 2013-12-20
AU2895502A (en) 2002-07-01
WO2002049552A2 (en) 2002-06-27
US20040053818A1 (en) 2004-03-18
US7169755B2 (en) 2007-01-30
EP1343444B1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
US20070173448A1 (en) Solution for removing cataracts via liquefracture
US5273056A (en) Use of combinations of viscoelastics during surgery
JP4146910B2 (en) Ophthalmic formulation of sodium hyaluronate active ingredient for ophthalmic surgery
US8529938B2 (en) Combinations of viscoelastics for use during surgery
US20080020017A1 (en) Intraocular Irrigating Solution Having Improved Flow Characteristics
WO2005097225A1 (en) New viscoelastic composition, method of use and package
US7084130B2 (en) Intraocular irrigating solution having improved flow characteristics
EP1023077B1 (en) Opthalmic composition
AU2005231687B2 (en) New free-radical scavenger containing viscoelastic composition, methods of use and package
US7578809B2 (en) Surface modified viscoelastics for ocular surgery
AU2005216946B2 (en) Alginate viscoelastic composition, method of use and package
ES2209170T3 (en) SWITCHABLE VISCOELASTIC SYSTEMS CONTAINING GALACTOMANAN AND BORATE POLYMERS.
EP1455750B1 (en) Viscoelastic ophthalmic compositions comprising hyaluronic acid and chondroitin sulphate
US7363928B2 (en) Dilution resistant viscoelastic compositions
WO2003059391A2 (en) Viscoelastics for ocular surgery
US20060003964A1 (en) Dilution resistant viscoelastic compositions
WO2007008206A1 (en) Dilution resistant viscoelastic compositions
US20090258955A1 (en) Intraocular irrigating solution having improved flow characteristics

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION